Novartis Price To Sales Ratio from 2010 to 2024
| NVS Stock | USD 104.87 1.06 1.02% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 4.52060424 | Current Value 3.86 | Quarterly Volatility 0.82117546 |
Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 B, Interest Expense of 550.6 M or Selling General Administrative of 15 B, as well as many indicators such as Price To Sales Ratio of 3.86, Dividend Yield of 0.0241 or PTB Ratio of 3.23. Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.
Novartis | Price To Sales Ratio |
Latest Novartis' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Novartis AG ADR over the last few years. Price to Sales Ratio is figured by comparing Novartis AG ADR stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Novartis sales, a figure that is much harder to manipulate than other Novartis AG ADR multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Novartis' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novartis' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 4.16 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Novartis Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 3.63 | |
| Geometric Mean | 3.53 | |
| Coefficient Of Variation | 22.63 | |
| Mean Deviation | 0.61 | |
| Median | 3.71 | |
| Standard Deviation | 0.82 | |
| Sample Variance | 0.67 | |
| Range | 3.1311 | |
| R-Value | 0.39 | |
| Mean Square Error | 0.62 | |
| R-Squared | 0.15 | |
| Significance | 0.15 | |
| Slope | 0.07 | |
| Total Sum of Squares | 9.44 |
Novartis Price To Sales Ratio History
About Novartis Financial Statements
Novartis shareholders use historical fundamental indicators, such as Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Novartis investors may analyze each financial statement separately, they are all interrelated. The changes in Novartis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Novartis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 4.52 | 3.86 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.